June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Prospective, longitudinal feasibility study: daily self-imaging with home OCT in neovascular age-related macular degeneration
Author Affiliations & Notes
  • Yingna Liu
    Retina Service, OCB, Boston, Massachusetts, United States
    Department of Ophthalmology, Tufts Medical Center, Boston, Massachusetts, United States
  • Nancy M Holekamp
    Retina Services, Pepose Vision Institute, Chesterfield, Missouri, United States
  • Jeffrey S Heier
    Retina Service, OCB, Boston, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Yingna Liu None; Nancy Holekamp Allergan, Annexon, Apellis, Bayer, Cardinal, Clearside Biosciences, EyePoint Pharmaceuticals, Gemini, Genentech, Gyroscope, Katalyst Surgical, Nacuity, NGM, Notal Vision, Novartis, Ocuphire, Outlook Therapeutics, Regeneron, Thea Laboratoires, Stealth Biosciences, Code C (Consultant/Contractor); Jeffrey Heier Notal Vision, Code C (Consultant/Contractor)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 2320. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Yingna Liu, Nancy M Holekamp, Jeffrey S Heier; Prospective, longitudinal feasibility study: daily self-imaging with home OCT in neovascular age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 2022;63(7):2320.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To validate the feasibility and performance of the Notal Vision Home OCT (NVHO) system for daily self-imaging at home, and to characterize retinal fluid dynamics in neovascular AMD (nAMD).

Methods : In this prospective observational study, 15 participants who have at least one eye with nAMD undergoing anti- VEGF treatments performed daily self-imaging at home with NVHO for 3 months. Scans were uploaded to the cloud, analyzed by the Notal OCT Analyzer (NOA), evaluated by human experts for fluid presence and compared with in-office OCT scans. Weekly self-scan rate, image quality, scan duration were obtained; agreement between NOA and human expert grading for fluid presence and agreement between NVHO and in-office OCT scans for fluid presence, central subfield retinal thickness (CST) and retinal fluid volume, characteristics of fluid dynamic during the study and in response to treatments were analyzed.

Results : The mean weekly scan frequency was 5.7±0.9 scans per week, and 93% of scans were eligible for NOA analyses. Mean scan time was 42 seconds. NOA and human experts agreed on the fluid status in 83% of scans and discrepancies were limited to trace amounts of fluid. NVHO scans analyzed by NOA and in-office OCT scans graded by human experts agreed on the fluid status in 96% of cases. CST and retinal fluid volume measurements from home OCT and in-office OCT scans demonstrated Pearson correlation coefficients of r = 0.90 and r = 0.92, respectively. Novel parameters such as retinal fluid volume, area under the retinal fluid volume curve (AUC) demonstrated wide variations in fluid exudation and fluid load over time among patients. Parameters, such as the rate of reduction in fluid volume in the first week after treatments and AUC between treatments captured the speed and duration of response to anti-VEGF agents.

Conclusions : Daily home OCT imaging is feasible among patients with nAMD. It demonstrated good agreement with human expert grading for retinal fluid identification, and excellent agreement with in-clinic OCT scans. Home OCT allows for detailed graphical and mathematical analyses of retinal fluid volume trajectories, including novel parameters to inform clinical decision making.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×